AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Choosing between fixed and flexible credit card rewards can be challenging. Explore the pros and cons to find the best option for you.
24,294 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
CoreWeave unleashed resilient US-scale growth with a massive backlog, while Nebius posted stronger margins on a small...
Christopher Nolan delivers a blockbuster opening for The Odyssey, outperforming Oppenheimer and marking his best star...
Two North American midstream giants posted earnings that point to divergent paths for dividend investors in 2026. ENB...
As AI momentum intensifies, investors re-evaluate three tech leaders. This report examines MSFT, DELL, and INTEL to a...
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
A week of silence fuels speculation and headlines. This article breaks down the money side of celebrity rumors, from ...
Toast is showing renewed momentum as its growth engine—international expansion, a growing enterprise pipeline, and a ...
Mission Produce enters 2026 with a mix of hedges, growing demand, and a tight supply chain. This guide breaks down wh...
A surge in AI-focused crypto has investors weighing a $500 bet. This article breaks down how the technology works, th...
A new science council linked to Trump signals a stronger link between AI and crypto policy. This morning minute exami...
Archer’s Q1 2026 numbers set the tone for the year. This article breaks down the earnings call, explains what really ...